Who is sponsoring NCT05183399?

NCT05183399 is sponsored by W.L.Gore & Associates.

What drugs are being tested in NCT05183399?

Interventions in NCT05183399: GORE® VIABAHN® Endoprosthesis.

What condition does NCT05183399 study?

NCT05183399 studies Iatrogenic Vessel Injury.

Is NCT05183399 still recruiting?

NCT05183399 is currently completed. Last updated 10 January 2023.

Last reviewed 2023-01-10 · How we verify

NCT05183399

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of Patients With Traumatic or Iatrogenic Vessel Injuries

Completed Last updated 10 January 2023

What this trial tests

trial testing GORE® VIABAHN® Endoprosthesis in Iatrogenic Vessel Injury in 30 participants. Completed in 14 February 2021.

Timeline

1 December 2016

Primary endpoint
19 May 2017

14 February 2021

Quick facts

Lead sponsor	W.L.Gore & Associates
Status	Completed
Study type	OBSERVATIONAL
Enrollment	30
Start date	1 December 2016
Primary completion	19 May 2017
Estimated completion	14 February 2021

Drugs / interventions tested

GORE® VIABAHN® Endoprosthesis

Conditions studied

Iatrogenic Vessel Injury — all drugs for Iatrogenic Vessel Injury →

Sponsor

W.L.Gore & Associates — full company profile →

Who can join

Eligibility, any sex, with Iatrogenic Vessel Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to confirm device efficacy and safety of the GORE® VIABAHN® Endoprosthesis (hereafter "VB device") for the treatment of traumatic or iatrogenic vessel injury in thoracic, abdominal, and pelvic arteries (except the aorta, coronary, brachiocephalic, carotid, vertebral and pulmonary arteries).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Evaluation of VIABAHN<sup>Ⓡ</sup> Endoprosthesis for Thoracic, Abdominal, and Pelvic Artery Injuries.
Anai H, Tanaka T, Nishiofuku H, Ikeda O, et al · · 2025 · PMID 41001076 · DOI 10.22575/interventionalradiology.2024-0038

Verify or expand the search:

Other trials of GORE® VIABAHN® Endoprosthesis

Trials testing the same drug.

NCT04706273 — GORE® VIABAHN® Endoprosthesis Post-Marketing Surveillance Study (JPS 16-03) · completed

Other W.L.Gore & Associates trials

Trials by the same sponsor.

NCT07147569 — TAMBE Japan Post-Marketing Surveillance · recruiting
NCT06827990 — GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections · NA · recruiting
NCT06872905 — Real-World Data Collection of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis When Used in Covered Endovascular · recruiting
NCT06578741 — GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis Post-Approval Study · NA · enrolling by invitation
NCT06174376 — Clinical Outcomes of the Gore Synthetic Cornea Device · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05183399 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by W.L.Gore & Associates
Last refreshed: 10 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05183399.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing